AlphaQuest LLC Has $462,000 Holdings in 10x Genomics $TXG

AlphaQuest LLC lifted its holdings in shares of 10x Genomics (NASDAQ:TXG) by 35.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 39,905 shares of the company’s stock after purchasing an additional 10,446 shares during the period. AlphaQuest LLC’s holdings in 10x Genomics were worth $462,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of TXG. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of 10x Genomics by 235.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,103,768 shares of the company’s stock worth $62,016,000 after purchasing an additional 4,987,195 shares during the period. Millennium Management LLC lifted its holdings in shares of 10x Genomics by 434.5% during the first quarter. Millennium Management LLC now owns 5,377,492 shares of the company’s stock worth $46,946,000 after purchasing an additional 4,371,327 shares during the period. Jacobs Levy Equity Management Inc. lifted its holdings in shares of 10x Genomics by 3,619.6% during the first quarter. Jacobs Levy Equity Management Inc. now owns 1,166,723 shares of the company’s stock worth $10,185,000 after purchasing an additional 1,135,356 shares during the period. ARK Investment Management LLC lifted its holdings in shares of 10x Genomics by 8.1% during the second quarter. ARK Investment Management LLC now owns 13,892,103 shares of the company’s stock worth $160,871,000 after purchasing an additional 1,046,390 shares during the period. Finally, Iron Triangle Partners LP acquired a new position in shares of 10x Genomics during the first quarter worth $8,730,000. Institutional investors and hedge funds own 84.68% of the company’s stock.

Insider Transactions at 10x Genomics

In other news, CEO Serge Saxonov sold 9,348 shares of the business’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $128,908.92. Following the completion of the sale, the chief executive officer directly owned 945,892 shares of the company’s stock, valued at $13,043,850.68. The trade was a 0.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Adam Taich sold 22,315 shares of the company’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $307,723.85. Following the completion of the sale, the chief financial officer directly owned 309,273 shares of the company’s stock, valued at $4,264,874.67. The trade was a 6.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 39,149 shares of company stock valued at $539,865 over the last three months. Corporate insiders own 10.03% of the company’s stock.

10x Genomics Price Performance

NASDAQ:TXG opened at $13.34 on Wednesday. The firm has a 50-day moving average of $12.87 and a 200-day moving average of $11.45. The company has a market cap of $1.66 billion, a PE ratio of -19.06 and a beta of 2.05. 10x Genomics has a one year low of $6.78 and a one year high of $18.21.

10x Genomics (NASDAQ:TXG) last posted its earnings results on Thursday, August 7th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of ($0.35) by $0.63. The company had revenue of $172.91 million during the quarter, compared to the consensus estimate of $139.36 million. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The firm’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.32) earnings per share. 10x Genomics has set its Q3 2025 guidance at EPS. On average, equities research analysts expect that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on TXG shares. Piper Sandler initiated coverage on shares of 10x Genomics in a report on Thursday, September 11th. They set a “neutral” rating and a $15.00 price target on the stock. Wall Street Zen upgraded shares of 10x Genomics from a “hold” rating to a “buy” rating in a report on Friday, October 3rd. Deutsche Bank Aktiengesellschaft set a $14.00 target price on shares of 10x Genomics and gave the company a “hold” rating in a report on Friday, August 8th. Canaccord Genuity Group set a $16.00 target price on shares of 10x Genomics in a report on Monday, August 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of 10x Genomics in a report on Tuesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $13.65.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.